Cardiovascular diseases (CVDs) represent∼ 31% of all global deaths, and hypertension
alone accounts for∼ 50% of these cases. Inflammation and subsequent fibrosis in heart …

Endothelial-to-mesenchymal transition (EndMT) has been shown to contribute to organ
fibrogenesis. We have reported that N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) restored …

Nanomedicines for treating chronic kidney disease (CKD) are on the horizon, yet their
delivery to renal tubules where tubulointerstitial fibrosis occurs remains inefficient. We report …

Background Renal fibrosis is the most common pathway leading to end-stage renal disease.
It is characterized by excess extracellular matrix (ECM) accumulation and renal tissue …

In this study, we make an elucidation toward both the therapeutic effect and the mechanism
of Shenqi Yanshen Formula (SQYSF) to chronic kidney disease (CKD). CKD mouse model …

N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous immunomodulatory
peptide that is generated from thymosin β4 (Tβ4) through stepwise hydrolysis, involving …

Idiopathic pulmonary fibrosis (IPF) is a progressive, life‐threatening lung disease with a poor
prognosis. N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (Ac‐SDKP) is a critical negative regulator …

Abstract N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (Ac‐SDKP) is a physiological antifibrotic
peptide that is hydrolysed by angiotensin I‐converting enzyme (ACE). The beneficial …

Fibroblast Growth Factors, Second Edition systematically introduces readers to FGF in the
fields of injury repair and regeneration, endocrinology and metabolism, structure and …

Fibrosis is a pathological process in which parenchymal cells are necrotic and excess
extracellular matrix (ECM) is accumulated due to dysregulation of tissue injury repair …